newsfilter
← Latest News
GlobeNewswire·

ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million

Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale proceeds are expected to enable ObsEva to resolve its current